Skip to main content

TFAP2A KO cell line available to order. KO validated by Western blot. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 2 and Insertion of the selection cassette in exon 2.

Be the first to review this product! Submit a review

Images

Western blot - Human TFAP2A (Transcription factor AP-2-alpha) knockout HeLa cell line (AB265122), expandable thumbnail
  • Sanger Sequencing - Human TFAP2A (Transcription factor AP-2-alpha) knockout HeLa cell line (AB265122), expandable thumbnail
  • Sanger Sequencing - Human TFAP2A (Transcription factor AP-2-alpha) knockout HeLa cell line (AB265122), expandable thumbnail

Key facts

Cell type
HeLa
Species or organism
Human
Tissue
Cervix
Form
Liquid
Knockout validation
Sanger Sequencing, Western blot
Mutation description
Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 2 and Insertion of the selection cassette in exon 2

Alternative names

AP-2, AP-2 transcription factor, AP2-alpha, AP2A_HUMAN, AP2TF, Activating enhancer-binding protein 2-alpha, Activator protein 2, BOFS, FLJ51761, TFAP 2, TFAP 2A, Transcription factor AP 2 alpha (activating enhancer binding protein 2 alpha), Transcription factor AP-2-alpha

Recommended products

TFAP2A KO cell line available to order. KO validated by Western blot. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 2 and Insertion of the selection cassette in exon 2.

Key facts

Cell type
HeLa
Form
Liquid
Mutation description
Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 2 and Insertion of the selection cassette in exon 2
Disease
Adenocarcinoma
Concentration
Loading...

Properties

Gene name
TFAP2A
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing, Western blot

Quality control

STR analysis
CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level
EU: 2 US: 2
Adherent/suspension
Adherent
Gender
Female

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium
DMEM (High Glucose) + 10% FBS
Cryopreservation medium
Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Storage

Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Notes

Recommended control: Human wild-type HeLa cell line (ab255928). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.
Activity summary

Transcription factor AP-2-alpha also known as TFAP2A or AP-2 is a protein acting as an important regulator in cellular processes. It weighs approximately 52 kDa. TFAP2A is known for its role in binding specific DNA sequences to regulate target gene transcription. It expresses highly in neural crest-derived tissues as well as in the placenta breast and skin. This transcription factor plays an essential role in embryonic development cell proliferation and differentiation.

Biological function summary

TFAP2A contributes significantly to the regulation of gene expression involved in essential developmental and cellular processes. It acts as part of a complex with other transcription factors allowing it to coordinate the expression of a variety of genes linked to cell growth and apoptosis. AP-2 also regulates genes involved in neural development and skin morphogenesis. Its interaction with other factors such as AP-2γ and AP-2β enhances its functionality indicating a complex mechanism of action.

Pathways

TFAP2A engages in critical signalling circuits such as the MAPK and Wnt pathways which are essential for cell cycle regulation and embryonic development. Within these pathways related proteins like AP-2γ and AP-594 interact with TFAP2A further illustrating its role in signal transduction. These relationships highlight the importance of TFAP2A in orchestrating cellular responses to growth signals and environmental cues.

Associated diseases and disorders

TFAP2A has links to a range of pathological conditions including cancer and neural crest-related disorders. In melanoma for example TFAP2A's regulatory role affects genes associated with tumor growth and metastasis. The protein's interaction with other transcription factors like AP-647 may influence cancer progression and therapy response. Additionally the dysregulation of TFAP2A affects neural crest development potentially leading to congenital disorders. Understanding these interactions assists in unraveling the molecular basis of such diseases and informs therapeutic strategies.

Product promise

We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.

In the unlikely event of one of our products not working as expected, you are covered by our product promise.

Full details and terms and conditions can be found here:
Terms & Conditions.

3 product images

Downloads

Product protocols

For this product, it's our understanding that no specific protocols are required. You can:

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com